Addus HomeCare (NASDAQ:ADUS) EVP Cliff Donald Blessing Sells 177 Shares of Stock

Addus HomeCare Corporation (NASDAQ:ADUS) EVP Cliff Donald Blessing sold 177 shares of the business’s stock in a transaction on Wednesday, February 25th. The stock was sold at an average price of $105.36, for a total value of $18,648.72. Following the sale, the executive vice president owned 12,361 shares in the company, valued at approximately $1,302,354.96. The trade was a 1.41% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link.

Cliff Donald Blessing also recently made the following trade(s):

• On Tuesday, February 24th, Cliff Donald Blessing sold 350 shares of Addus HomeCare stock. The shares were sold at an average price of $107.14, for a total value of $37,499.00.

Addus HomeCare Price Performance

Shares of NASDAQ:ADUS traded down $0.51 during midday trading on Friday, hitting $103.52. 14,471 shares of the stock were exchanged, compared to its average volume of 233,037. Addus HomeCare Corporation has a twelve month low of $88.96 and a twelve month high of $124.43. The company has a current ratio of 1.80, a quick ratio of 1.66 and a debt-to-equity ratio of 0.11. The company has a 50 day moving average price of $109.41 and a 200-day moving average price of $113.01. The stock has a market cap of $1.92 billion, a P/E ratio of 19.85, a PEG ratio of 1.49 and a beta of 0.91.

Key Stories Impacting Addus HomeCare

Here are the key news stories impacting Addus HomeCare this week:

• Positive Sentiment: Stephens retained an “Overweight” rating on ADUS and set a $135 price target (trimmed from $140), keeping a constructive analyst opinion that supports medium-term upside. Read More.
• Positive Sentiment: Large institutional investors increased positions in recent quarters (Capital Research, Vanguard, Wasatch, State Street and others), signaling continued institutional confidence and buying power underneath the stock. Read More.
• Neutral Sentiment: Short-interest reporting is inconsistent across feeds (some entries show 0 shares, others show a material rise), creating data noise — investors should confirm with official FINRA/exchange data before sizing positions. Read More.
• Negative Sentiment: Insiders sold multiple tranches of stock on Feb. 24–25: CEO R. Dirk Allison sold several thousand shares (~7,300 across filings) and numerous EVPs also liquidated positions — concentrated insider selling often weighs on sentiment and can pressure the share price. Read More.
• Negative Sentiment: Reported short interest increased materially in February to roughly 1.15M shares (~6.5% of float, ~4.6 days to cover in mid-February) — a larger short book can amplify downside on negative headlines and increase volatility. Read More.
• Negative Sentiment: Media picked up a “pessimistic forecast” narrative tied to Stephens’ shorter-term expectations after the PT cut, which can reinforce selling pressure despite the retained Overweight rating. Read More.

Wall Street Analyst Weigh In

ADUS has been the topic of several research reports. Royal Bank Of Canada reiterated an “outperform” rating and issued a $139.00 price target on shares of Addus HomeCare in a research report on Wednesday. Truist Financial set a $135.00 price target on Addus HomeCare and gave the stock a “buy” rating in a research report on Wednesday, January 7th. BMO Capital Markets began coverage on Addus HomeCare in a research report on Thursday, November 13th. They issued a “market perform” rating and a $120.00 price objective on the stock. TD Cowen reiterated a “buy” rating on shares of Addus HomeCare in a research report on Wednesday, November 5th. Finally, Barclays reduced their target price on shares of Addus HomeCare from $117.00 to $112.00 and set an “underweight” rating on the stock in a report on Tuesday. One analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $134.33.

Institutional Trading of Addus HomeCare

Hedge funds have recently added to or reduced their stakes in the business. Global Retirement Partners LLC increased its stake in shares of Addus HomeCare by 395.7% during the 4th quarter. Global Retirement Partners LLC now owns 233 shares of the company’s stock valued at $25,000 after acquiring an additional 186 shares during the last quarter. Larson Financial Group LLC grew its holdings in Addus HomeCare by 133.3% in the third quarter. Larson Financial Group LLC now owns 238 shares of the company’s stock valued at $28,000 after purchasing an additional 136 shares during the period. Acumen Wealth Advisors LLC purchased a new stake in Addus HomeCare in the fourth quarter valued at approximately $29,000. Arax Advisory Partners increased its position in Addus HomeCare by 95.8% during the fourth quarter. Arax Advisory Partners now owns 280 shares of the company’s stock worth $30,000 after purchasing an additional 137 shares during the last quarter. Finally, Private Trust Co. NA raised its stake in Addus HomeCare by 65.5% during the fourth quarter. Private Trust Co. NA now owns 283 shares of the company’s stock worth $30,000 after purchasing an additional 112 shares during the period. 95.35% of the stock is owned by institutional investors and hedge funds.

About Addus HomeCare

Addus HomeCare (NASDAQ: ADUS) is a leading provider of home and community-based care services for elderly, disabled, and medically complex individuals across the United States. Through a network of company-owned and franchise locations, the company delivers a broad spectrum of non-medical personal care and licensed home health services designed to support clients’ independence and quality of life.

The company’s core offerings include personal care assistance—covering daily living activities, medication reminders, and light housekeeping—and skilled home health services delivered under the supervision of registered nurses and licensed therapists.